Pancreatitis

Pancreatitis is inflammation of the pancreas, a gland that produces digestive enzymes and hormones involved in blood glucose regulation. Acute pancreatitis develops suddenly and may resolve, although severe episodes can cause tissue death and organ failure. Chronic pancreatitis is a persistent fibroinflammatory disorder that can produce irreversible structural damage and loss of pancreatic function. (niddk.nih.gov)

The disease has several causes, including gallstones, heavy alcohol use, metabolic abnormalities, genetic susceptibility, and immune-mediated disorders. Its importance extends beyond abdominal illness: pancreatic damage can interfere with nutrient absorption and contribute to diabetes mellitus, while severe acute disease may require prolonged hospital care. Understanding pancreatitis involves distinguishing its clinical forms, identifying their causes, assessing tissue injury and complications, and examining established diagnostic and treatment approaches. (niddk.nih.gov)

Pancreatic anatomy and mechanisms of injury

The pancreas lies behind the stomach, with its head enclosed by the C-shaped duodenum and its body and tail extending toward the spleen. Small pancreatic ducts converge on the main pancreatic duct, which carries digestive secretions into the duodenum. The gallbladder stores bile made by the liver and releases it through the biliary ducts; the common bile duct and pancreatic duct usually share an outlet near the major duodenal papilla. This close anatomical relationship explains why a migrating gallstone can obstruct pancreatic drainage without originating in the pancreas itself. The gland has two distinct functional compartments: its exocrine tissue supplies digestive juice to the intestine, whereas endocrine islets produce hormones, including insulin and glucagon, that regulate blood glucose. (seer.cancer.gov)

Exocrine acinar cells manufacture digestive enzymes, including amylase for starch digestion, lipase for fat digestion, and protease precursors for protein digestion. Normal secretion separates enzyme production inside the gland from digestive activity in the intestinal lumen. In particular, acinar cells produce trypsinogen, an inactive precursor that is secreted into the small intestine and converted to trypsin; trypsin then digests protein and activates other digestive enzymes. Premature activation within pancreatic tissue breaches this separation, allowing proteolytic activity to damage cells rather than food. This mechanism is important, but pancreatic injury is not simply an uncontrolled enzyme reaction: experimental studies also demonstrate inflammatory signaling that proceeds independently of trypsinogen activation. (seer.cancer.gov)

Acinar-cell injury involves disruption of intracellular calcium control and energy production. Sustained elevation of cytosolic calcium can overload mitochondria, opening their permeability transition pores and reducing production of adenosine triphosphate, the cell’s principal energy currency. Energy depletion compromises calcium clearance, reinforcing calcium overload and promoting necrotic cell death. A 2015 experimental study demonstrated this sequence in mouse models and in human pancreatic acinar cells and tissue preparations, linking mitochondrial dysfunction with impaired intracellular recycling, enzyme activation, and inflammatory responses. These findings describe interacting cellular mechanisms rather than a single obligatory initiating event in every case. (gut.bmj.com)

Damaged acinar cells also initiate inflammation by releasing molecular danger signals and activating inflammatory gene expression. Nuclear factor κB is one transcription factor connecting cellular stress to the production of cytokines and other inflammatory mediators. Chemokines recruit neutrophils and macrophages, which amplify tissue injury and signaling. For example, a 2021 experimental study found that extracellular HMGB1 promoted neutrophil extracellular-trap formation and stimulated macrophage processing of interleukin-1β. Inflammatory mediators can enter the circulation, connecting localized pancreatic damage with inflammation in distant organs; severe systemic effects therefore need not depend on pancreatic infection. The detailed contribution of individual pathways varies between experimental models and human disease. (niddk.nih.gov)

Persistent structural damage involves activation of pancreatic stellate cells, which occupy spaces around acini and between pancreatic lobules. In their resting state, these cells contain vitamin A-rich lipid droplets. During activation they acquire a myofibroblast-like phenotype and synthesize extracellular-matrix proteins, including collagen types I and III, fibronectin, and laminin. Minoti Apte and colleagues isolated stellate-shaped cells from rat pancreas in 1998; in the same year, Max Bachem and colleagues characterized corresponding cells in rat and human tissue and demonstrated their matrix-producing activity. When injury and inflammatory stimulation persist, excessive matrix deposition produces fibrosis, replacing functional tissue with scar and disrupting the gland’s architecture. This fibrogenic response provides a mechanism for lasting damage rather than merely prolonged swelling. (pubmed.ncbi.nlm.nih.gov)

Clinical forms and classification

Acute pancreatitis is a sudden inflammatory episode affecting the pancreas, with a clinical course ranging from brief, self-limited illness to prolonged disease with organ failure. Recurrent acute pancreatitis denotes at least two documented, distinct acute episodes separated by clinical recovery, rather than continuing symptoms or complications from one attack. It is distinguished from established chronic pancreatitis by the absence of demonstrable chronic pancreatic disease. Some research definitions require at least three symptom- and complication-free months between attacks; interval requirements vary among classification frameworks. Repetition alone does not establish irreversible structural damage. (pmc.ncbi.nlm.nih.gov)

The revised Atlanta classification, developed in 2012 by an international working group including Peter A. Banks, distinguishes two morphological forms. Interstitial edematous pancreatitis involves inflammation and edema without recognizable tissue necrosis. Necrotizing pancreatitis involves tissue death in the pancreas, surrounding tissues, or both. Morphological type and clinical severity are separate classifications: necrosis does not automatically mean severe disease. (pubmed.ncbi.nlm.nih.gov)

Atlanta also distinguishes overlapping early and late phases. The early phase, usually the first week, is dominated by the systemic response to pancreatic injury; severity chiefly reflects organ failure and its duration. The late phase may continue for weeks or months, with persistent systemic inflammation or evolving local complications. It occurs only in moderately severe or severe disease. (doi.org)

The three severity grades are mild, with neither organ failure nor local or systemic complications; moderately severe, with organ failure resolving within 48 hours, local complications, or exacerbation of pre-existing disease, but no persistent organ failure; and severe, with organ failure persisting for more than 48 hours. Respiratory, cardiovascular, and renal failure are assessed using the modified Marshall score; a score of at least 2 in any system establishes organ failure. Thus, a pancreatic collection without persistent organ failure is moderately severe, whereas persistent respiratory failure establishes severe disease. (pubmed.ncbi.nlm.nih.gov)

Chronic pancreatitis is not simply an acute attack of unusually long duration. The 2020 American College of Gastroenterology guideline describes it mechanistically as a fibroinflammatory syndrome arising when susceptible individuals develop persistent pathological responses to pancreatic injury or stress. Established disease may feature fibrosis, pancreatic atrophy, calcification, and distorted or narrowed ducts, but these findings are not uniformly present throughout its course. Structural damage and functional impairment also vary: reduced digestive secretion and diabetes mellitus need not appear together or at the same stage. Some patients have no preceding recognized acute attack. Conversely, a prolonged necrotizing acute episode does not, by duration alone, establish chronic pancreatitis. (doi.org)

Causes and susceptibility

Gallstones cause acute pancreatitis when a stone migrates from the gallbladder into the common bile duct and obstructs the outlet near the junction with the pancreatic duct. Obstruction impedes pancreatic secretion and can initiate injury even when the stone subsequently passes into the duodenum; persistent obstruction is therefore not necessary for an attack. Very small stones, termed microlithiasis, can also be responsible. Gallstone disease is an important cause of acute episodes, but gallstones do not ordinarily cause chronic pancreatitis directly. (niddk.nih.gov)

Heavy alcohol exposure and tobacco smoking are distinct susceptibility factors, particularly for recurrent acute and chronic disease. Alcohol consumption alone does not establish that an episode is alcohol-induced: other causes can coexist, and NICE’s 2018 guideline explicitly cautions against this attribution solely because a person drinks. In a 2009 analysis led by Dhiraj Yadav, the North American Pancreatitis Study 2 included 540 patients with chronic pancreatitis, 460 with recurrent acute pancreatitis, and 695 controls recruited at 20 US centers during 2000–2006. Very heavy drinking—defined in that study as at least five drinks daily—was associated with chronic pancreatitis after adjustment for smoking and other factors, with an odds ratio of 3.10 and a 95% confidence interval of 1.87–5.14. Cigarette smoking independently showed a dose-dependent association with both recurrent acute and chronic pancreatitis, rather than merely identifying people who also drank heavily. The study’s drinking category was an analytical definition, not a universal threshold for alcohol-associated injury. (nice.org.uk)

Metabolic causes include severe hypertriglyceridemia and hypercalcemia. The relevant lipid abnormality is markedly elevated triglycerides, not simply elevated cholesterol or any diagnosis of hyperlipidemia. Risk rises particularly at triglyceride concentrations exceeding 1,000–2,000 mg/dL, although susceptibility varies and no concentration guarantees an attack. Severe elevations can reflect inherited lipid disorders combined with secondary factors such as poorly controlled diabetes mellitus, obesity, alcohol exposure, or medications. Proposed injury mechanisms include pancreatic lipase releasing toxic free fatty acids from triglyceride-rich particles and impaired microcirculation associated with chylomicron accumulation. Hypercalcemia is a less common cause; primary hyperparathyroidism is one documented underlying condition, although pancreatitis occurs in only a subset of affected patients. (ncbi.nlm.nih.gov)

Medication-associated pancreatitis requires distinguishing causal evidence from coincidence. Jasmine Saini and colleagues’ 2023 revised evidence classification identified randomized-trial evidence for azathioprine, 6-mercaptopurine, and didanosine, whereas many other alleged associations rested on low-quality case reports. Timing after exposure is not sufficient by itself: credible attribution depends on confirmed pancreatitis, exclusion of common alternative causes, and the strength of drug-specific evidence. Other recognized causes include abdominal trauma and infections. Endoscopic retrograde cholangiopancreatography (ERCP) can itself provoke pancreatitis through mechanical, thermal, or chemical injury to the papilla or pancreatic duct; resulting edema can obstruct drainage. The American Society for Gastrointestinal Endoscopy’s 2023 guideline cited approximate rates of 8% in average-risk and 15% in high-risk procedures, illustrating that this is a procedure-related complication rather than an unexplained spontaneous episode. (pmc.ncbi.nlm.nih.gov)

Structural causes include pancreatic-duct obstruction and pancreatic or ampullary tumors; pancreatic cancer may occasionally first become apparent through pancreatitis. Anatomical variants such as pancreas divisum are also considered in etiologic investigation, but identifying a variant does not automatically prove causation. The American Gastroenterological Association’s 2022 expert review emphasized uncertainty surrounding intervention for divisum-associated recurrent attacks, with objective evidence of impaired outflow being an important distinction. Idiopathic pancreatitis denotes disease for which no cause has been identified after investigation, not a specific mechanism. Further assessment can reveal previously unrecognized microlithiasis, a structural lesion, or inherited susceptibility; genetic and autoimmune causes constitute separate etiologic categories. (niddk.nih.gov)

Hereditary, autoimmune, and pediatric disease

Hereditary pancreatitis classically denotes an inherited predisposition to recurrent pancreatic inflammation, most clearly established for certain pathogenic variants of PRSS1, the gene encoding cationic trypsinogen. High-penetrance variants such as p.Arg122His and p.Asn29Ile promote inappropriate trypsin activity within the pancreas and can cause autosomal dominant disease, often beginning in childhood. Other PRSS1 variants have lower penetrance or act principally as susceptibility factors. Each child of a heterozygous carrier has a 50% probability of inheriting the variant, but inheritance does not guarantee symptomatic disease. Reported penetrance for p.Arg122His and p.Asn29Ile has ranged from approximately 80% to 96% across studied populations. Consequently, an asymptomatic carrier and a person with established pancreatitis are not equivalent clinical categories. (ncbi.nlm.nih.gov)

SPINK1, CTRC, and CFTR influence susceptibility through different protective pathways. SPINK1 encodes pancreatic secretory trypsin inhibitor, while CTRC encodes chymotrypsin C, which participates in controlling trypsinogen activation and degradation. Predisposing variants can weaken protection against premature enzyme activity. CFTR encodes an epithelial ion channel involved in pancreatic ductal chloride and bicarbonate secretion; some variants impair bicarbonate transport without producing the typical pulmonary manifestations of cystic fibrosis. These genes cannot be interpreted simply as positive or negative “pancreatitis genes”: the particular variant, whether one or both gene copies are affected, and accompanying genetic or environmental factors determine its significance. Susceptibility variants are not necessarily sufficient to cause disease independently. Family history therefore informs interpretation, but absence of affected relatives does not exclude inherited susceptibility; reduced penetrance and newly arising PRSS1 variants can obscure familial patterns. Alcohol exposure and smoking can add environmental risk to an inherited predisposition. (ncbi.nlm.nih.gov)

Autoimmune pancreatitis comprises two distinct clinicopathological forms. Type 1 is a pancreatic manifestation of IgG4-related disease, a systemic fibroinflammatory disorder that can also involve the bile ducts, salivary glands, kidneys, and lymph nodes. Its characteristic tissue pattern, lymphoplasmacytic sclerosing pancreatitis, combines lymphocyte and plasma-cell infiltration, storiform—whorled or cartwheel-like—fibrosis, and obliterative phlebitis, in which inflammation narrows or closes veins. IgG4-positive plasma cells are prominent, and serum IgG4 may be elevated. Type 2, also termed idiopathic duct-centric pancreatitis, instead features granulocytic epithelial lesions: neutrophils infiltrate and damage pancreatic duct epithelium. It generally lacks marked IgG4 elevation and is associated with inflammatory-bowel-disease, particularly ulcerative colitis. Type 1 predominantly affects older men, whereas type 2 has a younger age distribution and a more equal sex distribution. The international consensus criteria published in 2011 integrate imaging, serology, other-organ involvement, histology, and an optional treatment-response criterion rather than relying on a single blood result. (pubmed.ncbi.nlm.nih.gov)

Children can develop acute, recurrent acute, or chronic pancreatitis. Recurrent acute disease entails distinct attacks with intervening resolution, whereas chronic disease requires evidence of persistent pancreatic damage rather than merely frequent episodes. Childhood causes include biliary or ductal obstruction, medications, abdominal trauma, systemic illness, metabolic disorders, and genetic susceptibility. Infants and toddlers may exhibit irritability or poorly localized symptoms rather than the characteristic adult pain pattern. The INSPPIRE pediatric consensus incorporates sweat chloride testing and PRSS1 analysis into investigation of recurrent or chronic disease, with SPINK1, CFTR, and CTRC testing identifying additional susceptibility factors. A negative newborn cystic-fibrosis screen does not replace evaluation for CFTR-related pancreatic disease. (pmc.ncbi.nlm.nih.gov)

A 2016 multicenter INSPPIRE study enrolled 301 children, with a mean age of 11.9 years: 155 had recurrent acute pancreatitis and 146 had chronic pancreatitis. Among those genetically tested, at least one pancreatitis-associated variant was identified in 49 of 102 children with recurrent disease (48%) and 86 of 118 with chronic disease (73%); these referral-cohort figures are not population prevalence estimates. Chronic disease was associated with more emergency visits, hospitalizations, and interventions. Pediatric burden also includes disruption of schooling and threats to adequate nutrition during growth. Persistent digestive impairment can produce weight loss and fat-soluble vitamin deficiencies, making growth trajectories and nutritional status important components of pediatric assessment. (pubmed.ncbi.nlm.nih.gov)

Symptoms and clinical presentation

Acute pancreatitis typically presents with upper abdominal pain that may radiate to the back. Its onset can be sudden or gradual, and the pain may persist for several days rather than occur only as brief episodes. Intensity varies from mild discomfort to severe pain. Associated symptoms include nausea, vomiting, fever, and a rapid pulse; examination may reveal abdominal swelling or tenderness. Patients often appear markedly unwell, although the precise combination of symptoms varies between individuals. The location, duration, and accompanying features of the pain are therefore more informative descriptions of presentation than any single symptom considered alone. (niddk.nih.gov)

In chronic pancreatitis, pain may recur in episodes or become persistent. It commonly affects the upper abdomen, can extend to the back, and may worsen after eating. Some patients develop constant, severe pain, whereas others have little or no pain despite established pancreatic disease. Pain may also diminish as the disease progresses; disappearance of pain does not necessarily indicate restoration of pancreatic function. Some people remain without recognizable symptoms until functional complications become apparent. Consequently, the clinical presentation of chronic disease ranges from a predominantly painful syndrome to one in which digestive symptoms or weight loss are the principal manifestations. (niddk.nih.gov)

Impaired digestion may produce diarrhea, loose stools, and greasy, foul-smelling stools, a pattern termed steatorrhea. Weight loss may accompany these bowel changes, sometimes together with bloating, excessive gas, or abdominal discomfort. These manifestations reflect inadequate digestion of nutrients when pancreatic digestive-enzyme delivery is insufficient, rather than simply the presence of abdominal inflammation. Steatorrhea can occur with or without diarrhea, so neither symptom is obligatory for the other. In chronic pancreatitis, unintended weight loss and oily stools may be prominent even when pain is not the chief complaint; the underlying exocrine functional deficit is distinct from the pain syndrome. (pubmed.ncbi.nlm.nih.gov)

Jaundice, visible as yellow discoloration of the skin and whites of the eyes, can accompany pancreatitis when bile drainage is obstructed. A particularly characteristic presentation of type 1 autoimmune pancreatitis is painless jaundice: Mayo Clinic reports this finding in approximately 80% of affected patients. Dark urine and pale stools may accompany the overlapping biliary presentation. Autoimmune disease may otherwise cause few symptoms, and upper abdominal pain can be absent; type 2 autoimmune pancreatitis can instead present with repeated attacks of acute pancreatitis. These differences concern clinical presentation rather than merely the duration or intensity of pain. (niddk.nih.gov)

Autoimmune pancreatitis may be associated with generalized enlargement of the pancreas or with a focal pancreatic mass. In combination with painless jaundice or unexplained weight loss, this can closely resemble pancreatic cancer. The resemblance is both clinical and structural: neither an apparently painless presentation nor the finding of a mass by itself distinguishes inflammation from malignancy. Mayo Clinic describes the distinction as requiring a combination of imaging, blood-test findings, and, where appropriate, tissue assessment, rather than reliance on a single symptom or characteristic feature. (mayoclinic.org)

Diagnosis and assessment

Acute pancreatitis is diagnosed when at least two of three findings are present: characteristic acute, persistent upper abdominal pain, often radiating to the back; serum lipase or amylase activity at least three times the laboratory’s upper limit of normal; and characteristic pancreatic abnormalities on imaging. These criteria were standardized in the 2012 revised Atlanta classification. When characteristic pain and the enzyme threshold are both present, imaging is not required solely to establish the diagnosis. Conversely, imaging can establish the second criterion when enzyme concentrations are below the threshold, including after delayed presentation. Lipase is generally preferred to amylase because it remains elevated longer. An isolated enzyme elevation is insufficient: elevated concentrations also occur in other disorders, and their magnitude does not measure disease severity. (doi.org)

Establishing pancreatitis and identifying its cause are separate investigations. History-taking examines previous attacks, biliary disease, alcohol exposure, medications, recent procedures, trauma, and family history. Laboratory assessment includes liver chemistry, triglycerides, and calcium: abnormal bilirubin or liver-enzyme results may indicate biliary obstruction, whereas marked hypertriglyceridemia or hypercalcemia identifies a possible metabolic cause. The American College of Gastroenterology’s 2024 guideline identifies triglycerides above 1,000 mg/dL as particularly suggestive of a causal role when gallstones and substantial alcohol exposure are absent. Alcohol consumption alone does not establish alcohol-associated disease. Unexplained episodes can prompt investigation for microlithiasis, anatomical abnormalities, autoimmune disease, or obstructing tumors; age over 40 years and a prolonged or recurrent unexplained course increase concern for a pancreatic tumor. (nice.org.uk)

Imaging modalities answer different questions. Transabdominal ultrasonography is principally used to identify gallstones and biliary dilatation; intestinal gas can limit visualization of the pancreas. Contrast-enhanced computed tomography depicts pancreatic inflammation, impaired tissue enhancement associated with necrosis, and surrounding collections. Routine admission CT is not necessary when the diagnosis is already established; the 2024 guideline reserves it for diagnostic uncertainty or failure to improve within 48–72 hours after admission. Early scans may underestimate evolving necrosis. Magnetic resonance imaging provides complementary soft-tissue assessment, while magnetic resonance cholangiopancreatography delineates the bile and pancreatic ducts without endoscopic instrumentation. Endoscopic ultrasonography places the transducer near the pancreas and can identify small biliary stones or subtle pancreatic abnormalities missed by other examinations. MR cholangiopancreatography and endoscopic ultrasonography can investigate suspected duct stones without diagnostic endoscopic retrograde cholangiopancreatography. (niddk.nih.gov)

Chronic pancreatitis requires assessment of persistent structural disease rather than application of the acute enzyme threshold. Relevant imaging findings include pancreatic calcification, ductal irregularity or dilatation, and parenchymal atrophy. The 2020 American College of Gastroenterology guideline places CT or MRI first in the diagnostic sequence, with endoscopic ultrasonography used when uncertainty remains; secretin-enhanced MR cholangiopancreatography can provide additional ductal information when suspicion remains high. Early disease is difficult to establish because structural changes may be absent or nonspecific, and minor endoscopic-ultrasound abnormalities do not necessarily demonstrate chronic pancreatitis. Serum amylase and lipase may be normal despite established disease. Pancreatic-function testing complements imaging: fecal elastase assesses exocrine dysfunction, while specialist direct tests measure stimulated pancreatic secretion. Functional impairment alone does not establish chronic pancreatitis, and fecal elastase is less sensitive for mild insufficiency; watery stools can produce falsely low concentrations through dilution. (doi.org)

Severity assessment is distinct from diagnostic confirmation and requires repeated evaluation. The revised Atlanta framework assesses respiratory, cardiovascular, and renal function using the modified Marshall score; a score of at least 2 in any one system defines organ failure. Relevant measurements include oxygenation, blood pressure and its response to fluids, and serum creatinine. Persistence beyond 48 hours distinguishes persistent from transient organ failure. Initial risk assessment also considers systemic inflammatory response, hemodynamic status, blood urea nitrogen, and hematocrit. Neither an admission scan nor a prognostic score reliably determines the eventual course, and a high lipase concentration does not establish severe disease. Serial clinical and laboratory findings therefore carry information that a single diagnostic measurement cannot provide. (doi.org)

Complications and functional consequences

The 2012 revised Atlanta classification distinguishes four pancreatic and peripancreatic collections by their contents and maturation. In interstitial edematous pancreatitis, an acute peripancreatic fluid collection contains fluid without necrotic debris, lacks a defined wall, and occurs during the first four weeks; most resolve spontaneously. A pancreatic pseudocyst is an encapsulated, predominantly fluid collection with little or no necrotic material, usually developing after four weeks. Its wall consists of inflammatory and fibrous tissue rather than an epithelial lining. In necrotizing pancreatitis, an acute necrotic collection contains variable amounts of fluid and dead pancreatic or peripancreatic tissue during the first four weeks. Walled-off necrosis is the mature, encapsulated counterpart, generally forming after at least four weeks. Thus, a mature collection containing substantial necrotic debris is not a pseudocyst. (doi.org)

Necrotic tissue may remain sterile or become infected. Gas within a collection, bloodstream infection, sepsis, or clinical deterioration can indicate infected necrosis, although no single feature is present in every case. Infection adds to the risks associated with tissue destruction and systemic inflammation. Severe acute disease can produce respiratory failure, cardiovascular failure with circulatory shock, or renal failure, singly or together; organ failure can also occur without infected necrosis. Persistence beyond 48 hours is the defining feature of severe acute pancreatitis in the revised Atlanta classification. Bleeding is another potentially serious complication. (gastro.org)

Disruption of the pancreatic duct permits enzyme-rich secretions to escape, sustaining collections or producing fistulas—abnormal communications with other spaces or the body surface. Leakage into the abdominal cavity can cause pancreatic ascites, while leakage into the chest can produce a pancreatic pleural effusion. Necrosis across the pancreatic neck or body may isolate a viable upstream segment from the main drainage route, creating disconnected pancreatic duct syndrome; continued secretion from that segment can cause recurrent collections or a persistent external fistula. Duct narrowing or blockage also complicates acute and chronic disease. Biliary obstruction impedes bile drainage, while pancreatic duct obstruction impedes pancreatic secretion; necrotic collections may additionally obstruct the gastrointestinal lumen. (niddk.nih.gov)

Exocrine pancreatic insufficiency develops when pancreatic digestive-enzyme quantity or activity falls below that required for normal digestion. In chronic pancreatitis, acinar-cell destruction and impaired delivery of secretions reduce intestinal digestion, particularly of fat. Consequences include steatorrhea, weight loss, protein-energy malnutrition, and deficiencies of fat-soluble vitamins A, D, E, and K. Inadequate digestion consequently limits nutrient absorption: maldigestion is the pancreatic defect, whereas malabsorption describes its downstream intestinal consequence. Chronic disease is also associated with reduced bone density, osteoporosis, and fractures, extending its functional effects beyond the pancreas. (ncbi.nlm.nih.gov)

Destruction of pancreatic islets can cause pancreatogenic diabetes, often termed type 3c diabetes. Unlike type 1 diabetes, its defining mechanism is not autoimmune beta-cell destruction; unlike conventional type 2 diabetes, it arises from pancreatic disease rather than primarily from insulin resistance. Loss of insulin secretion may coexist with impaired glucagon secretion, weakening the counter-regulatory response to hypoglycemia. Malabsorption and inconsistent food intake can further destabilize blood glucose. These categories are not mutually exclusive: type 1 or type 2 diabetes can coexist with chronic pancreatitis, and exocrine insufficiency alone does not establish pancreatic diabetes. (pmc.ncbi.nlm.nih.gov)

Chronic pancreatitis is associated with increased pancreatic cancer risk, but malignant transformation is not inevitable. In Albert B. Lowenfels and colleagues’ 1993 historical cohort of 2,015 patients from six countries, estimated cumulative cancer risk among patients followed for at least two years was 1.8% at ten years and 4.0% at twenty years after pancreatitis diagnosis. Risk differs between subgroups, particularly in PRSS1-related hereditary pancreatitis: published estimates by age 70 have ranged from 18.8–40% in earlier studies to 7.2% in a 2018 study. These cohort-specific estimates are not interchangeable with an individual prognosis. (nejm.org)

Treatment of acute pancreatitis

Hospital treatment combines circulatory support, pain relief, nutritional support, and management of organ dysfunction. Intravenous crystalloid administration is adjusted through repeated assessment of blood pressure, urine output, kidney-function tests, and signs of fluid overload, rather than continued at a fixed aggressive rate. Analgesia may include nonsteroidal anti-inflammatory drugs or opioids, selected according to pain severity and contraindications. Organ failure may require intensive-care admission and respiratory, cardiovascular, or renal support. (pure.eur.nl) The 2022 WATERFALL randomized controlled trial, led by Enrique de-Madaria, compared aggressive and moderate resuscitation using lactated Ringer’s solution. It was stopped after 249 participants because fluid overload occurred in 20.5% of the aggressive-treatment group versus 6.3% of the moderate-treatment group, without a significant reduction in moderately severe or severe pancreatitis. These findings support monitored resuscitation that balances restoration of circulation against excess fluid accumulation. (nejm.org)

Routine prolonged fasting is not part of standard treatment. Oral feeding resumes as tolerated; food need not be withheld solely because pancreatic inflammation is present. Vomiting or other clear barriers to feeding can temporarily limit oral intake. When oral intake is inadequate, enteral nutrition delivers nutrients through a tube into the stomach or small intestine. NICE guidance specifies starting enteral feeding within 72 hours of presentation in moderately severe or severe disease. Intravenous, or parenteral, nutrition has a narrower role: it is used when enteral feeding fails or is contraindicated, rather than as the default means of “resting” the pancreas. (nice.org.uk)

Antibiotics are used for established infection or strongly suspected infected pancreatic necrosis, not routinely to prevent infection in sterile pancreatitis or sterile necrosis. Findings supporting suspected infection include gas within a necrotic collection, bloodstream infection, sepsis, or clinical deterioration consistent with infection. When infected necrosis is suspected, intravenous agents capable of penetrating necrotic tissue are selected, with subsequent treatment informed by microbiological findings. Routine antifungal treatment is also not recommended. Antibiotic treatment and decisions about drainage are coordinated rather than treated as interchangeable interventions. (nice.org.uk)

For gallstone-associated disease, endoscopic retrograde cholangiopancreatography (ERCP) permits bile-duct stone extraction and biliary decompression. Early ERCP is indicated when acute cholangitis accompanies pancreatitis; without cholangitis, a demonstrated common-bile-duct stone can justify selective ERCP. Predicted severity alone does not justify routine early ERCP. Cholecystectomy—removal of the gallbladder—is generally performed during the same admission for mild biliary pancreatitis to prevent recurrence. In moderately severe or severe disease, especially with necrosis and peripancreatic collections, surgery is delayed until local complications have substantially resolved. (pure.eur.nl)

Infected necrosis and persistently symptomatic collections are managed through a staged, or “step-up,” approach. Drainage can be performed endoscopically through the stomach or duodenum, or percutaneously through the skin, depending on anatomy and clinical condition. Persistent infection or symptoms despite drainage may require necrosectomy, the removal of dead tissue, using endoscopic or minimally invasive surgical techniques; open surgery remains an option when less invasive approaches are unsuitable or unsuccessful. Debridement is preferably delayed for about four weeks to allow the collection to organize, but deterioration may necessitate earlier drainage. Sterile necrosis can also warrant intervention when it causes persistent pain, nutritional failure, or gastrointestinal or biliary obstruction; its presence alone is not an indication for removal. (pubmed.ncbi.nlm.nih.gov)

Management of chronic and autoimmune pancreatitis

Chronic-disease care combines gastroenterology, pain medicine, dietetics, endocrinology, and, when necessary, pancreatic surgery and psychological services. Assessment extends beyond pain intensity to food intake, weight, pancreatic function, medication dependence, and the effects of illness on daily activity and quality of life. Psychological assessment addresses anxiety, depression, and substance-use problems without implying that pancreatic pain is solely psychological. Analgesic treatment may include non-opioid drugs and agents targeting neuropathic pain; opioids used for refractory symptoms require continuing assessment of benefit and adverse effects. The 2020 American College of Gastroenterology guideline includes alcohol and smoking cessation in chronic-disease management, while acknowledging limited evidence about their effects on established disease progression. (pmc.ncbi.nlm.nih.gov)

Pancreatic enzyme replacement therapy treats inadequate digestive secretion rather than the underlying fibrosis. Oral preparations deliver lipase, proteases, and amylase with food, improving nutrient absorption and reducing steatorrhea. The American Gastroenterological Association’s 2023 guidance specifies administration during meals, with adult starting doses of at least 40,000 USP lipase units per meal and approximately half that amount with snacks, subsequently adjusted to food intake and response. Nutritional management includes adequate energy intake, monitoring and replacement of fat-soluble vitamins, and avoidance of excessively restrictive diets. Enzyme replacement is not an established treatment primarily for pancreatic pain: the 2020 ACG guideline advises against using supplements for that purpose. NICE recommends at least annual assessment for exocrine insufficiency and malnutrition in adults, and bone-density assessment every two years. (gastro.org)

Management of pancreatic diabetes is coordinated with nutritional and enzyme treatment. NICE distinguishes care for people who do not require insulin from insulin-treated disease, for which insulin delivery, glucose monitoring, and structured education follow relevant insulin-dependent diabetes guidance. Its pancreatitis guideline specifies HbA1c monitoring at least every six months and six-monthly assessment of people with type 3c diabetes for potential benefit from insulin therapy. These measures address continuing endocrine deterioration rather than assuming that glucose regulation remains stable after diagnosis. (nice.org.uk)

Procedural treatment is principally relevant when pain accompanies pancreatic duct obstruction. Endoscopic retrograde cholangiopancreatography can extract small duct stones and place stents across strictures; larger stones may require extracorporeal shock-wave or intraductal lithotripsy. Surgical drainage connects a dilated duct to the intestine, whereas an enlarged inflammatory pancreatic head may require a head-directed resection combined with drainage. Endoscopy is less invasive but can involve repeated procedures; surgery generally provides more durable relief in selected obstructive disease. In the 2020 ESCAPE randomized trial, Yama Issa and colleagues studied 88 patients with painful chronic pancreatitis, a dilated main duct, and recently initiated opioid treatment. Early surgery produced a lower integrated Izbicki pain score over 18 months than an endoscopy-first strategy—37 versus 49—and fewer interventions, with medians of one versus three. These results concern a defined obstructive population, not every chronic pain syndrome. (gastro.org)

Autoimmune pancreatitis requires specialist confirmation because pancreatic enlargement or a mass can resemble pancreatic cancer. Imaging, serology, and, where appropriate, tissue sampling establish diagnostic support before a carefully supervised steroid trial. Prednisone or prednisolone commonly produces rapid improvement; selected patients with obstructive jaundice also undergo biliary drainage. Relapse is substantially more frequent in type 1 disease—approximately 30–50%—than in type 2 disease, where it occurs in fewer than 10%. Recurrent disease may require further corticosteroid treatment or steroid-sparing therapy, including azathioprine, mycophenolate, or rituximab. Treatment also includes monitoring associated organ involvement, and steroid responsiveness does not replace evaluation for malignancy. (mayoclinic.org)

Total pancreatectomy with islet autotransplantation is reserved for selected patients with disabling, refractory chronic or recurrent pancreatitis. The pancreas is removed, its islets are isolated, and the patient’s own cells are usually infused into the liver through the portal vein. The graft can preserve some insulin secretion without transplant immunosuppression, but insulin independence is not assured. The 2014 PancreasFest recommendations emphasize multidisciplinary selection, residual islet function, and exclusion of contraindications such as known pancreatic cancer. Removal eliminates pancreatic digestive secretion, making lifelong enzyme replacement necessary; continuing diabetes surveillance and nutritional follow-up remain essential, and pain can persist despite removal of the organ. (pmc.ncbi.nlm.nih.gov)

Epidemiology, natural history, and disease burden

Population estimates distinguish new cases, existing disease, and hospital use. A 2017 meta-analysis of population-based cohorts estimated acute-pancreatitis incidence at 33.74 cases per 100,000 person-years and chronic-pancreatitis incidence at 9.62; these pooled estimates combined different populations and ascertainment methods rather than describing one worldwide surveillance system. Japan’s nationwide survey of patients treated in hospitals during 2016, published in 2020, estimated 78,450 acute-pancreatitis patients, equivalent to 61.8 per 100,000 inhabitants using the total national population as denominator. This hospital-treated estimate is not interchangeable with first-ever disease incidence. Acute disease is episodic, making annual occurrence more informative than point prevalence; neither measure should be equated with admission counts, which can include repeated stays by the same person. (pubmed.ncbi.nlm.nih.gov)

For chronic disease, Dhiraj Yadav and colleagues’ 2011 population-based study in Olmsted County, Minnesota, identified 106 incident cases during 1977–2006 through medical-record review and Mayo Clinic diagnostic criteria, including 17 diagnosed only at autopsy. Age- and sex-adjusted incidence was 4.05 per 100,000 person-years; point prevalence on January 1, 2006, was 41.76 per 100,000 residents. Rates were standardized to the 2000 US White population, and median age at diagnosis was 58 years, limiting direct comparison with pediatric populations or populations with different demographic compositions. Japan’s 2016 hospital survey, using its 2009 diagnostic criteria, estimated prevalence of definite or probable chronic pancreatitis at 44.5 per 100,000, while separately classified early disease contributed another 3.5 per 100,000. These categories and ascertainment methods differ from the Minnesota study’s criteria. (pubmed.ncbi.nlm.nih.gov)

Age and sex distributions partly reflect the distribution of etiologies. In Japan’s 2016 acute-pancreatitis sample, the male-to-female ratio was 2.0; mean onset ages were 59.9 years in males and 66.5 in females. Alcohol-associated disease accounted for 42.8% of male cases, whereas gallstones accounted for 37.7% of female cases. In the Minnesota chronic-pancreatitis cohort, 56% were male and 51% had alcohol-associated disease; among Japan’s definite or probable chronic cases in 2016, 72% were alcohol-associated. Such differences describe the studied populations, not universal biological effects of sex or geography, and comparisons also depend on diagnostic thresholds and access to care. (pubmed.ncbi.nlm.nih.gov)

Most acute episodes resolve within several days, although severe disease can require prolonged hospitalization. Recovery does not exclude later recurrence. Sharanya Sankaran and colleagues’ 2015 meta-analysis included 14 studies and 8,492 patients: the pooled proportion experiencing recurrent acute pancreatitis was 22%. Chronic pancreatitis developed in approximately 10% after a first acute episode and 36% among patients with recurrent episodes. These estimates combined differing follow-up periods and definitions; they are not fixed annual probabilities. Smoking, alcohol exposure, and male sex were associated with progression. The findings support a possible acute–recurrent–chronic trajectory, but most patients after a first episode did not develop established chronic disease during the observed follow-up. (niddk.nih.gov)

Acute mortality is concentrated in severe disease rather than distributed uniformly across episodes. A 2021 APPRENTICE study of 1,544 patients at 22 international centers reported overall mortality of 2.5%; 11% developed organ failure persisting beyond 48 hours. Mortality among patients with persistent failure of one, two, or three organ systems was approximately 4%, 33%, and 48%, respectively. Hospital-based cohorts therefore require severity stratification when describing prognosis. Chronic disease has a longer burden: the Minnesota population study found survival below that expected for age- and sex-matched residents, although this all-cause survival difference does not establish that every excess death was directly caused by pancreatic injury. (pmc.ncbi.nlm.nih.gov)

Chronic pancreatitis also imposes nutritional, occupational, and quality-of-life burdens. Impaired digestion can produce malnutrition, while endocrine dysfunction contributes to diabetes; persistent pain adds limitations beyond these functional consequences. In an analysis of 1,024 chronic-pancreatitis participants recruited through US NAPS2 studies during 2000–2014, mean Short Form-12 physical and mental component scores were 36.7 and 42.4, respectively, on scales standardized to a population mean of 50. Constant pain and pain-related disability or unemployment were independently associated with poorer scores. Because recruitment occurred predominantly in specialist centers, these measurements characterize a clinical cohort rather than all people with chronic pancreatitis. (niddk.nih.gov)

Development of knowledge and research priorities

The original Atlanta classification emerged from an international symposium held on September 11–13, 1992, involving 40 authorities from six medical disciplines and 15 countries. Edward L. Bradley III published its consensus definitions in 1993, providing shared terminology for acute pancreatitis and its complications and a basis for comparing results between institutions. The 2012 revision, published by Peter A. Banks and colleagues in Gut in 2013, incorporated accumulated clinical and imaging evidence. It distinguished mild, moderately severe, and severe disease, identified persistent organ failure lasting more than 48 hours as the defining feature of severe pancreatitis, and standardized descriptions of fluid and necrotic collections. These distinctions made study populations and outcomes more comparable: a collection containing necrotic tissue could no longer be treated as interchangeable with a fluid-only pseudocyst. (pubmed.ncbi.nlm.nih.gov)

A major advance in genetics occurred in 1996, when David C. Whitcomb and colleagues identified a cationic trypsinogen gene, PRSS1, mutation causing hereditary pancreatitis. This connected an inherited clinical syndrome to disrupted control of a digestive enzyme, rather than simply to the appearance of a damaged gland. Subsequent discoveries implicated CFTR, SPINK1, and CTRC, connecting susceptibility to ductal secretion, trypsin inhibition, and protease regulation. Research also moved beyond rare familial mutations: a 2012 genome-wide association study identified susceptibility loci at PRSS1–PRSS2 and the X-linked CLDN2 region, with evidence of interaction between the latter and alcohol exposure. These findings supported a multifactorial model in which variants and environmental exposures influence risk without necessarily determining an individual’s outcome. In 2016, Whitcomb and an international group proposed a mechanistic definition of chronic pancreatitis centered on persistent pathological responses to injury or stress, separating susceptibility, disease activity, and established structural damage. (pubmed.ncbi.nlm.nih.gov)

Early detection research seeks biomarkers that identify pancreatic injury before advanced calcification or functional failure and predict which patients will progress. The US PROCEED study, whose design was published in 2018 by Dhiraj Yadav and colleagues, established a prospective observational framework combining clinical characterization, biological samples, and longitudinal assessment. Its goals include testing candidate biomarkers and defining progression across different disease stages. A critical distinction is between a marker that separates existing patient groups and one that predicts future disease: demonstrating an association with established pancreatitis does not itself establish prognostic value. Prospective follow-up also permits assessment of whether biological signals precede, accompany, or follow changes in pancreatic structure and function. (doi.org)

Quantitative magnetic resonance imaging provides concrete examples of this distinction. A multicenter PROCEED analysis included 820 participants enrolled between June 2017 and December 2021. Mean pancreas-to-spleen T1 signal-intensity ratios were 1.30 in participants with chronic abdominal pain, 1.22 in those with acute or recurrent acute pancreatitis, and 1.03 in those with definite chronic pancreatitis. The MINIMAP study, published in 2022, examined 101 participants at seven US centers and evaluated T1 relaxation time, extracellular-volume fraction, diffusion, and pancreatic fat. Such measurements investigate tissue changes beyond conventional ductal morphology. Although these studies demonstrated differences between groups, their cross-sectional findings did not establish that the measurements could forecast individual progression; this remains distinct from the established clinical use of imaging to identify structural disease. (pmc.ncbi.nlm.nih.gov)

Mechanistic priorities include determining how inflammation becomes persistent, how stellate-cell activation and matrix deposition sustain fibrosis, and how peripheral nerve injury and central sensitization contribute to pain. An NIDDK workshop held on July 27, 2016, emphasized improved disease models, earlier diagnosis, and measurable intermediate endpoints for therapeutic trials. Research linking pancreatitis with diabetes mellitus examines the contributions of islet loss and impaired insulin action and the distinction between pancreatic diabetes and other diabetes types. Work on pancreatic cancer addresses inflammatory injury, tissue remodeling, and malignant transformation, alongside the problem of distinguishing inflammatory masses from tumors. These questions require biomarkers and models that discriminate mechanisms and disease states rather than treating fibrosis, pain, endocrine dysfunction, and cancer risk as equivalent outcomes. (pmc.ncbi.nlm.nih.gov)

References

1. Book 4 - Human Anatomy as Related to Tumor Formationseer.cancer.gov
2. Definition & Facts for Gallstones - NIDDKniddk.nih.gov
3. INTRODUCTION AND BACKGROUNDniddk.nih.gov
4. Story of Discovery: Genetic Insights into Pancreatitis - NIDDKniddk.nih.gov
5. Intra-acinar trypsinogen activation is required for early pancreatic injury but not for inflammation during acute pancreatitispmc.ncbi.nlm.nih.gov
6. Acute & Chronic Pancreatitis - NIDDKniddk.nih.gov
7. Activation of Nuclear Factor-κB in Acinar Cells Increases the Severity of Pancreatitis in Micepmc.ncbi.nlm.nih.gov
8. High-mobility group box protein-1 induces acute pancreatitis through activation of neutrophil extracellular trap and subsequent production of IL-1βpubmed.ncbi.nlm.nih.gov
9. LincRNA-EPS alleviates severe acute pancreatitis by suppressing HMGB1-triggered inflammation in pancreatic macrophagespubmed.ncbi.nlm.nih.gov
10. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culturepubmed.ncbi.nlm.nih.gov
11. Identification, culture, and characterization of pancreatic stellate cells in rats and humanspubmed.ncbi.nlm.nih.gov
12. Acute and Chronic Pancreatitispmc.ncbi.nlm.nih.gov
13. Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Summary of the Working Group on Drug Development and Trials in Recurrent Acute Pancreatitis (RAP) at the National Institute of Diabetes and Digestive and Kidney Diseases Workshoppmc.ncbi.nlm.nih.gov
14. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensuspubmed.ncbi.nlm.nih.gov
15. ACG Clinical Guideline: Chronic Pancreatitisdoi.org
16. Pancreatitis Overview - GeneReviews®ncbi.nlm.nih.gov
17. Symptoms & Causes of Pancreatitis - NIDDKniddk.nih.gov
18. Recommendations | Pancreatitis | Guidance | NICEnice.org.uk
19. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitispubmed.ncbi.nlm.nih.gov
20. Pancreatitis Secondary to Hypertriglyceridemia - Endotextncbi.nlm.nih.gov
21. Primary hyperparathyroidism presenting as acute pancreatitis: An institutional experience with review of the literaturepmc.ncbi.nlm.nih.gov
22. Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised)pmc.ncbi.nlm.nih.gov
23. ASGE guideline on post-ERCP pancreatitis prevention strategies: summary and recommendationsasge.org
24. New CPU alert: Endoscopic approach to recurrent acute and chronic pancreatitisgastro.org
25. PRSS1-Related Hereditary Pancreatitis - GeneReviews®ncbi.nlm.nih.gov
26. SPINK1, PRSS1, CTRC, and CFTR Genotypes Influence Disease Onset and Clinical Outcomes in Chronic Pancreatitispmc.ncbi.nlm.nih.gov
27. Autoimmune pancreatitis (AIP) type 1 and type 2: an international consensus study on histopathologic diagnostic criteriapubmed.ncbi.nlm.nih.gov
28. Autoimmune pancreatitis - Symptoms and causes - Mayo Clinicmayoclinic.org
29. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatologypubmed.ncbi.nlm.nih.gov
30. Definitions of Pediatric Pancreatitis and Survey of Current Clinical Practices: Report From INSPPIREpmc.ncbi.nlm.nih.gov
31. The Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report from the NASPGHAN Pancreas Committeepmc.ncbi.nlm.nih.gov
32. The Causal Evaluation of Acute Recurrent and Chronic Pancreatitis in Children: Consensus From the INSPPIRE Grouppmc.ncbi.nlm.nih.gov
33. Risk Factors Associated With Pediatric Acute Recurrent and Chronic Pancreatitis: Lessons From INSPPIREpubmed.ncbi.nlm.nih.gov
34. Identifying risk factors for pancreatitis in children - NIDDKniddk.nih.gov
35. Symptoms and causes - Mayo Clinicmayoclinic.org
36. Symptoms & Causes for Exocrine Pancreatic Insufficiency - NIDDKniddk.nih.gov
37. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review - PubMedpubmed.ncbi.nlm.nih.gov
38. Symptoms and causes - Mayo Clinicmayoclinic.org
39. Diagnosis and treatment - Mayo Clinicmayoclinic.org
40. American College of Gastroenterology Guidelines: Management of Acute Pancreatitispmc.ncbi.nlm.nih.gov
41. Recommendations | Pancreatitis | Guidance | NICEnice.org.uk
42. Diagnosis of Pancreatitis - NIDDKniddk.nih.gov
43. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)pmc.ncbi.nlm.nih.gov
44. ASGE | Case 18: Pancreasasge.org
45. Definition & Facts for Pancreatitis - NIDDKniddk.nih.gov
46. Management of pancreatic necrosis - American Gastroenterological Associationgastro.org
47. International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025doi.org
48. Detection, Evaluation and Treatment of Diabetes Mellitus in Chronic Pancreatitis: Recommendations from PancreasFest 2012pmc.ncbi.nlm.nih.gov
49. International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025pure.eur.nl
50. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosispubmed.ncbi.nlm.nih.gov
51. Mechanism, Assessment and Management of Pain in Chronic Pancreatitis: Recommendations of a Multidisciplinary Study Grouppmc.ncbi.nlm.nih.gov
52. Epidemiology, evaluation and management of exocrine pancreatic insufficiency (EPI)gastro.org
53. Effect of Early Surgery vs Endoscopy-First Approach on Pain in Patients With Chronic Pancreatitis: The ESCAPE Randomized Clinical Trialpmc.ncbi.nlm.nih.gov
54. Total Pancreatectomy and Islet Autotransplantation in Chronic Pancreatitis: Recommendations from PancreasFestpmc.ncbi.nlm.nih.gov
55. Total Pancreatectomy With Islet Auto-Transplantation (TPIAT): Summary of an NIDDK Workshoppmc.ncbi.nlm.nih.gov
56. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studiespubmed.ncbi.nlm.nih.gov
57. Clinical practice of acute pancreatitis in Japan: An analysis of nationwide epidemiological survey in 2016pubmed.ncbi.nlm.nih.gov
58. Incidence, prevalence, and survival of chronic pancreatitis: a population-based studypubmed.ncbi.nlm.nih.gov
59. Nationwide epidemiological survey of chronic pancreatitis in Japan: introduction and validation of the new Japanese diagnostic criteria 2019pubmed.ncbi.nlm.nih.gov
60. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysispubmed.ncbi.nlm.nih.gov
61. Mortality in acute pancreatitis with persistent organ failure is determined by the number, type, and sequence of organ systems affectedpmc.ncbi.nlm.nih.gov
62. Quality of life in Chronic Pancreatitis is determined by constant pain, disability/unemployment, current smoking and associated co-morbiditiespmc.ncbi.nlm.nih.gov
63. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992.pubmed.ncbi.nlm.nih.gov
64. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen genepubmed.ncbi.nlm.nih.gov
65. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitispubmed.ncbi.nlm.nih.gov
66. Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definitionpubmed.ncbi.nlm.nih.gov
67. T1 signal intensity ratio of the pancreas as an imaging biomarker for the staging of chronic pancreatitispmc.ncbi.nlm.nih.gov
68. Quantitative MRI of chronic pancreatitis: results from a multi-institutional prospective study, magnetic resonance imaging as a non-invasive method for assessment of pancreatic fibrosis (MINIMAP)pmc.ncbi.nlm.nih.gov
69. Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshoppmc.ncbi.nlm.nih.gov